Ratings by SMBC Nikko Securities (David Dai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2023 | Jounce Therapeutics | JNCE | Downgrade | Neutral (Outperform) |
1.10 (1.88) |
70.91% | Details | |
| 11/3/2022 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2022 | Agenus Inc. | AGEN | New Coverage | Outperform (N/A) |
2.04 (3.04) |
49.02% | Details | |
| 7/18/2022 | MacroGenics | MGNX | Downgrade | Neutral (Outperform) |
4.21 (4.58) |
8.79% | Details | |
| 5/16/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Xencor, Inc. | XNCR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2022 | Adicet Bio Inc. | ACET | New Coverage | Outperform (N/A) |
18.96 (8.23) |
-56.59% | Details | |
| 3/16/2022 | Inhibrx Inc. | INBX | New Coverage | Outperform (N/A) |
20.19 (93.30) |
362.11% | Details | |
| 3/16/2022 | Jounce Therapeutics | JNCE | New Coverage | Outperform (N/A) |
7.04 (1.88) |
-73.3% | Details | |
| 2/4/2022 | MacroGenics | MGNX | New Coverage | Outperform (N/A) |
11.41 (4.58) |
-59.86% | Details | |
| 1/21/2022 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
34.97 (14.01) |
-59.94% | Details | |
| 11/18/2021 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
18.17 (2.79) |
-84.65% | Details | |
| 10/8/2021 | Legand Biotech Corp. | LEGN | New Coverage | Outperform (N/A) |
52.48 (29.34) |
-44.09% | Details |
